According to a report on FirstWord Pharma some time yesterday, there are at least two — and maybe more — potential bidders for the assets of Dendreon. The good news for patients is therefore that sipuleucel-T (Provenge) will almost certainly continue to be available for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
The only named bidder at this time is Valeant, which has raised its bid to $400 million from an initial $296 million. The deadline for parties to submit bids to Dendreon is February 10, with an auction to be held on February 12 if Dendreon receives other offers.
Filed under: Management, Treatment | Tagged: Dendreon, Provenge, sipuleucel-T |
THE "NEW" PROSTATE CANCER INFOLINK 
What do you say we partner on this Mike? I can write a check…
I’m good for about $5.00!
Valeant prevailed at $400 million after second bidder dropped out. Valeant is an aggressive company known for cost cutting. Deal should close by end of February.